Cencora（COR）株式概要
Cencora, Inc.は、米国内外で医薬品の調達と販売を行っている。 詳細
COR Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cencora, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$304.00 |
| 52週高値 | US$377.54 |
| 52週安値 | US$271.00 |
| ベータ | 0.72 |
| 1ヶ月の変化 | -6.40% |
| 3ヶ月変化 | -16.38% |
| 1年変化 | 4.07% |
| 3年間の変化 | 80.96% |
| 5年間の変化 | 151.53% |
| IPOからの変化 | 10,194.18% |
最新ニュース
COR: CFO Transition And Disciplined Buybacks Will Support Long-Term Upside
Analysts have trimmed their price target on Cencora by about $5 to reflect slightly updated assumptions around fair value, revenue growth, profit margins, and future P/E, while still viewing the shares through a similar overall framework. What's in the News Cencora plans a leadership change, with long serving Chief Financial Officer James F.All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside
Apr 12COR: Rare Disease Collaborations And Distribution Reach Will Support Long-Term Upside
Analysts have kept their price target for Cencora steady at $407.92, citing only very small tweaks to inputs like revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the business. What's in the News Cencora announced that Chief Financial Officer James F.COR: Rare Disease Partnerships Will Support Long-Term Upside For Capital Markets Access
Analysts have adjusted their fair value estimate for Cencora to about $408 from $410, reflecting small tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E rather than a major shift in the story. What's in the News Cencora plans for Chief Financial Officer James F.Recent updates
COR: CFO Transition And Disciplined Buybacks Will Support Long-Term Upside
Analysts have trimmed their price target on Cencora by about $5 to reflect slightly updated assumptions around fair value, revenue growth, profit margins, and future P/E, while still viewing the shares through a similar overall framework. What's in the News Cencora plans a leadership change, with long serving Chief Financial Officer James F.All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside
Apr 12COR: Rare Disease Collaborations And Distribution Reach Will Support Long-Term Upside
Analysts have kept their price target for Cencora steady at $407.92, citing only very small tweaks to inputs like revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the business. What's in the News Cencora announced that Chief Financial Officer James F.COR: Rare Disease Partnerships Will Support Long-Term Upside For Capital Markets Access
Analysts have adjusted their fair value estimate for Cencora to about $408 from $410, reflecting small tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E rather than a major shift in the story. What's in the News Cencora plans for Chief Financial Officer James F.COR: Capital Markets And Rare-Disease Services Will Support Long-Term Upside
Analysts now place Cencora's fair value at $410.00, up from $403.79. This change reflects small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates in their models.COR: 3PL Expansion And M&A Options Will Shape Balanced Long-Term Upside
Analysts have nudged their price target for Cencora higher to about $404 from roughly $400, citing refreshed assumptions around revenue growth, profitability and a modestly higher future P/E multiple. What's in the News Cencora is expanding its third party logistics capabilities in the United States and Europe, including adding NextPharma Logistics across Germany, Austria and Switzerland and planning a new 3PL facility in Italy in 2026, alongside increased cold chain capacity across its European network (company announcement).Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Feb 12
COR: Buybacks And 3PL Expansion Will Support Long-Term Upside Potential
Analysts have nudged their projected fair value for Cencora to $399.80 from $396.80, citing updated assumptions around revenue growth, profit margins, the discount rate and a slightly lower future P/E multiple. What's in the News Cencora completed a share repurchase program totaling 4,895,419 shares, or 2.49% of shares, for US$1,118.1m under the buyback announced on May 1, 2024 (Buyback Tranche Update).COR: Global 3PL Expansion And Logistics Investments Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about US$397 from roughly US$388. This reflects refreshed assumptions on revenue growth, profit margins and future P/E levels in their models.COR: Global 3PL Buildout And Higher Dividend Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about $388, citing slightly lower modeled revenue growth, a modestly stronger profit margin, and a small uptick in assumed future P/E as key drivers of the updated view. What's in the News Cencora announced investments to expand its third party logistics capabilities in the United States and Europe, including broader specialty logistics services for pharmaceutical companies worldwide.COR: Global 3PL Expansion And Dividend Increases Will Offset Goodwill Impairment Risks
Analysts have slightly raised their price target on Cencora, increasing fair value by about 1.8 dollars per share as they factor in marginally stronger projected revenue growth, a modestly higher long term profit margin, and a steady future earnings multiple. What's in the News Cencora is making major investments to expand its third party logistics network, including a new 500,000 square foot 3PL facility in Texas by 2028 and a tripling of ultra low and cryogenic storage capacity in the United States, to support growing demand for specialty medicines such as cell and gene therapies (company announcement).COR: Automated Distribution Expansion And Margins Will Balance Storage And Dividend Risks
Analysts have modestly raised their price target for Cencora, increasing the estimated fair value by $2.71 to $384.79. This adjustment is based on slight improvements in profit margin expectations and valuation multiples.COR: Automated Expansion And Margin Gains Will Offset Ongoing Legal Risks
Analysts have raised their price target for Cencora, increasing the estimated fair value from $338.29 to $382.07. They cite strengthened profit margin expectations, even though there is a slightly higher discount rate and moderated revenue growth forecasts.COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution
Analysts have raised their price target for Cencora by $5 to $338.29. They cite updated forecasts for slightly lower near-term revenue growth, but a stronger overall fair value assessment.Digital Infrastructure And Specialty Services Will Redefine Healthcare Delivery
With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29. What's in the News Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 09
Cencora: Great Track Record And Outlook, But Valuation Does Not Offer Upside
Feb 25Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating
Sep 18株主還元
| COR | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | -1.4% | 3.5% | 0.8% |
| 1Y | 4.1% | -3.1% | 27.8% |
業界別リターン: COR過去 1 年間で-3.1 % の収益を上げたUS Healthcare業界を上回りました。
リターン対市場: CORは、過去 1 年間で27.8 % のリターンを上げたUS市場を下回りました。
価格変動
| COR volatility | |
|---|---|
| COR Average Weekly Movement | 4.6% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: COR 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CORの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1871 | 49,000 | Bob Mauch | www.cencora.com |
Cencora, Inc.は米国内外で医薬品の調達と販売を行っている。同社の米国ヘルスケアソリューション事業では、ジェネリック医薬品や注射剤、一般用医薬品、在宅医療用品・機器、関連サービスを、急性期病院や医療システム、独立系・チェーン系小売薬局、通信販売薬局、診療所、長期療養・代替施設薬局、その他の顧客に販売している；臨床試験サポート、製品承認後および商業化サポートサービス、バイオテクノロジーおよび製薬メーカー向けのデータ分析、アウトカムリサーチおよびその他のサービス、コンパニオンアニマルおよび畜産動物市場向けの医薬品、ワクチン、寄生虫駆除剤、診断薬、マイクロ飼料原料およびその他の製品、メーカー向けのセールスフォースサービス、腫瘍学など様々な病態を専門とする医師および病院や透析クリニックなどその他の医療提供者へのその他のサービスの提供。インターナショナル・ヘルスケア・ソリューションズ部門は、国際的な医薬品卸売および関連サービス、グローバルな商品化サービスを提供し、医薬品、その他のヘルスケア製品、関連サービスを薬局、医師、ヘルスセンター、病院に販売し、バイオ医薬品業界向けに特殊輸送およびロジスティクスサービスを提供している。旧社名はアメリソース・バーゲン・コーポレーションで、2023年8月に社名をセンコラ・インクに変更した。は1871年に設立され、ペンシルバニア州コンショホッケンに本社を置いている。
Cencora, Inc. 基礎のまとめ
| COR 基礎統計学 | |
|---|---|
| 時価総額 | US$59.14b |
| 収益（TTM） | US$1.63b |
| 売上高(TTM) | US$325.78b |
36.4x
PER（株価収益率0.2x
P/SレシオCOR は割高か？
公正価値と評価分析を参照収益と収入
| COR 損益計算書（TTM） | |
|---|---|
| 収益 | US$325.78b |
| 売上原価 | US$314.01b |
| 売上総利益 | US$11.77b |
| その他の費用 | US$10.15b |
| 収益 | US$1.63b |
直近の収益報告
Dec 31, 2025
次回決算日
May 06, 2026
| 一株当たり利益（EPS） | 8.35 |
| グロス・マージン | 3.61% |
| 純利益率 | 0.50% |
| 有利子負債／自己資本比率 | 378.0% |
COR の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.8%
現在の配当利回り27%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/03 03:25 |
| 終値 | 2026/05/01 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/09/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cencora, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。32
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |